PIK3CA

News

Celcuity eyes big market opportunity after breast cancer win

Celcuity shares rocket on a big win for its lead drug gedatolisib in advanced breast cancer, catapulting its value to almost $1.4 billion.

News

T-cells attacking cancer cell illustration of microscopic photos

Novartis scores first approval for PIK3CA breast cancer drug

The FDA has approved Novartis’ breast cancer drug Piqray (alpelisib), making it the first marketed treatment targeting the PIK3CA mutation in this disease.

News

NHS staff 'feel unprepared for digital transformation'

A survey of NHS workers has found that almost two-thirds feel they are unprepared for the digital transformation objectives of the 10-Year Plan.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Editor's Picks